Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Neotropix Initiates Phase II Lung Cancer Trial | Contract Pharma

What are you searching for?

Sign in

Neotropix Initiates Phase II Lung Cancer Trial

Neotropix began enrolling patients in a Phase II trial to assess the efficacy of the novel oncolytic virus, NTX-010, in patients with extensive stage small cell lung cancer (SCLC).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Neotropix began enrolling patients in a Phase II trial to assess the efficacy of the novel oncolytic virus, NTX-010, in patients with extensive stage small cell lung cancer (SCLC). NTX-010 has been shown to be highly selective for certain neuroendocrine tumor types including SCLC.

The current study is designed to determine activity of a single dose of NTX-010 when used immediately after completion of standard first line therapy for SCLC as NTX-010 replicates within the tumor generating more drug as it destroys the cancer cells.

Anthony Williams, M.D., chief medical officer at Neotropix, commented, “Oncolytic viruses are an innovative approach to cancer treatment in which the very specific destruction of cells by a virus is directed against a patient’s tumor cells, offering the ability to kill the cancer without affecting normal cells, resulting in significantly less side effects. Neotropix’s NTX-010 is highly unique among this class of agents in that it is an unengineered ‘natural product’ with innate anti-cancer activities.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters